Other Non-Current Liabilities
Neurocrine Biosciences Other Non-Current Liabilities increased by 18.8% to $260.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 43.7%, from $181.60M to $260.90M. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 86.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $29.00M | $8.30M | $12.30M | $19.70M | $28.00M | $17.10M | $29.70M | $41.30M | $88.50M | $68.60M | $106.30M | $120.50M | $141.10M | $135.00M | $166.20M | $181.60M | $210.10M | $195.70M | $219.70M | $260.90M |
| QoQ Change | — | -71.4% | +48.2% | +60.2% | +42.1% | -38.9% | +73.7% | +39.1% | +114.3% | -22.5% | +55.0% | +13.4% | +17.1% | -4.3% | +23.1% | +9.3% | +15.7% | -6.9% | +12.3% | +18.8% |
| YoY Change | — | — | — | — | -3.4% | +106.0% | +141.5% | +109.6% | +216.1% | +301.2% | +257.9% | +191.8% | +59.4% | +96.8% | +56.3% | +50.7% | +48.9% | +45.0% | +32.2% | +43.7% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's other non-current liabilities?
- Neurocrine Biosciences (NBIX) reported other non-current liabilities of $260.90M in Q1 2026.
- How has Neurocrine Biosciences's other non-current liabilities changed year-over-year?
- Neurocrine Biosciences's other non-current liabilities increased by 43.7% year-over-year, from $181.60M to $260.90M.
- What is the long-term trend for Neurocrine Biosciences's other non-current liabilities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's other non-current liabilities has grown at a 86.6% compound annual growth rate (CAGR), from $9.70M to $219.70M.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.